The NEJM review of HSDD therapeutics by Goldstein et al
For many, it's the first time they've been able to distinguish between physical hunger and psychological craving
The second was a matched cohort of 30,528 women, pairing each GLP-1 user with a nonuser who shared similar characteristics, including age, race, ethnicity, BMI, breast density, and diabetes status
Cardiovascular protection: Clinical trials have found that Semaglutide decreases the chances of major cardiovascular events, including heart attack and stroke, in people who are overweight or obese who have known cardiovascular disease
If youre experiencing unwanted blunting on one formulation, a different drug or dose may not have the same effect